Request a meeting with a VYEPTI sales representative in your area

Request a representative

Interested in discussing VYEPTI with a sales representative in your area? Request a meeting now.

Contact VYEPTI CONNECT to get access and reimbursement support

Contact VYEPTI CONNECT

VYEPTI CONNECT Liaisons are available to help you with access and reimbursement support and more, by phone.

Phone number: 833-4-VYEPTI (833-489-3784)

 

Available Monday through Friday, 8 am-8 pm (ET)

Fax number: 866-868-7071

Contact VYEPTI product support

VYEPTI product support

For general VYEPTI product support, please call
833-4-VYEPTI (833-489-3784).

Stay connected by signing up to receive updates

Stay connected

Want to keep up with the latest news and updates about migraine prevention with VYEPTI?

Support your patient’s treatment journey with resources from VYEPTI GO

VYEPTI GO

Discover the patient resources we have to support your patients along their VYEPTI treatment journey.

Report suspected adverse reactions to Lundbeck or FDA

Adverse reactions

To report suspected adverse reactions, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

If you have patients who are willing to share their VYEPTI stories, they may share their experiences here.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.